# MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer

> **NCT05462236** · PHASE2 · RECRUITING · sponsor: **AUM Biosciences Pte Ltd** · enrollment: 120 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Tinodasertib
- **DRUG:** Pembrolizumab
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT05462236
- **Lead sponsor:** AUM Biosciences Pte Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-14
- **Primary completion:** 2024-09-30
- **Final completion:** 2026-10-15
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05462236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05462236, "MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05462236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*